Molecular marker for diagnosing lupus nephritis concurrent pulmonary arterial hypertension disease and application thereof

A molecular marker, pulmonary arterial hypertension technology, used in disease diagnosis, analytical materials, biological testing, etc., can solve the problem that clinical features cannot be credibly explained.

Active Publication Date: 2019-09-17
PEKING UNIV THIRD HOSPITAL
View PDF12 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In the pathogenic process of systemic lupus erythematosus, the traditional theory holds that the classical pathway of immune complex activation of complement is the most important factor, but there are still many clinical features that cannot be credibly explained

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular marker for diagnosing lupus nephritis concurrent pulmonary arterial hypertension disease and application thereof
  • Molecular marker for diagnosing lupus nephritis concurrent pulmonary arterial hypertension disease and application thereof
  • Molecular marker for diagnosing lupus nephritis concurrent pulmonary arterial hypertension disease and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 Differential expression of complement pathway related proteins in lupus nephritis with pulmonary hypertension

[0038] Materials and Methods

[0039] Research object:

[0040] First, we retrospectively evaluated the cases of 389 patients who were diagnosed with lupus nephritis by renal biopsy at Peking University First Hospital from January 2002 to May 2009. The patients were diagnosed by chest echocardiography during their hospitalization. , And evaluate all types of renal vascular disease through renal pathological observation, including vascular immune complex deposition, arteriosclerosis, thrombotic microangiopathy, non-inflammatory necrotizing vascular disease, and true vasculitis. Furthermore, according to figure 1 According to the standard, 24 patients with lupus nephritis and pulmonary hypertension (LN-PAH) were selected for the study. The diagnosis of lupus nephritis is based on the standards of the American Rheumatology Association. PAH adopts the standa...

Embodiment 2

[0085] Example 2 Diagnosis of Lupus Nephritis Complicated with Pulmonary Hypertension Using Differential Proteins in the Complement Pathway

[0086] Seven patients with lupus nephritis newly admitted to Peking University First Hospital were selected to use complement H factor and complement Bb fragments as molecular markers to diagnose whether they were associated with pulmonary hypertension, and the results of right heart catheterization were used as controls.

[0087] The test results are shown in Table 5:

[0088] patient1234567 Factor H (μg / ml)253.00326.12469.56500.78189.65385.46156.27 Bb(μg / ml)1.200.720.690.611.290.692.11 Right heart catheterization test (+ / -) +---+-+

[0089] The results show that the use of complement factor H and complement Bb fragments as molecular markers can accurately diagnose or predict whether patients with lupus nephritis have pulmonary hypertension.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention aims to provide a molecular marker for diagnosing a lupus nephritis concurrent pulmonary arterial hypertension disease and application thereof. A complement factor h and a complement Bb fragment are used as molecular markers for diagnosis or prediction of the lupus nephritis concurrent pulmonary arterial hypertension disease, so that whether a patient with the lupus nephritis is concurrent with the pulmonary arterial hypertension or the onset risk can be accurately diagnosed or predicted. Compared with the right-sided heart catheterization and other invasive inspection means, the molecular marker and the application thereof are more suitable for clinical popularization.

Description

Technical field [0001] The present invention relates to molecular markers of diseases, in particular to molecular markers for diagnosing lupus nephritis and pulmonary hypertension and their uses. Background technique [0002] Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases in my country. The kidney is one of the organs most easily affected by systemic lupus erythematosus. Lupus nephritis (LN) is caused by systemic lupus erythematosus involving the kidneys One of the immune complex nephritis is the most common secondary glomerular disease. Pulmonary arterial hypertension (PAH) refers to changes in pulmonary vascular function and or structure caused by various reasons, characterized by progressive increases in pulmonary vascular resistance. As a common and serious complication of SLE, it is one of the main factors for poor prognosis of SLE patients One. [0003] The pathogenic mechanism of SLE-PAH is mainly the dysfunction of the vascular endothelium...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/58G01N33/564
CPCG01N33/6893G01N33/581G01N33/582G01N33/564G01N2800/104G01N2800/321G01N2800/347G01N2800/50G01N2333/4716
Inventor 李秋钰
Owner PEKING UNIV THIRD HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products